Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.87 Insider Own25.83% Shs Outstand6.46M Perf Week5.58%
Market Cap3.29M Forward P/E- EPS next Y- Insider Trans0.16% Shs Float5.92M Perf Month-23.57%
Income-12.40M PEG- EPS next Q-0.55 Inst Own4.85% Short Float0.51% Perf Quarter-53.76%
Sales0.00M P/S- EPS this Y-24.86% Inst Trans- Short Ratio0.35 Perf Half Y-58.26%
Book/sh-0.63 P/B- EPS next Y- ROA-265.15% Short Interest0.03M Perf Year-94.56%
Cash/sh0.04 P/C11.76 EPS next 5Y- ROE-1489.09% 52W Range0.37 - 8.10 Perf YTD-53.63%
Dividend Est.- P/FCF- EPS past 5Y-69.45% ROI- 52W High-94.90% Beta0.06
Dividend TTM- Quick Ratio0.16 Sales past 5Y0.00% Gross Margin- 52W Low11.81% ATR (14)0.05
Dividend Ex-Date- Current Ratio0.16 EPS Y/Y TTM21.44% Oper. Margin0.00% RSI (14)40.88 Volatility10.80% 11.20%
Employees4 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price21.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q54.40% Payout- Rel Volume1.73 Prev Close0.43
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsJul 03 Avg Volume85.42K Price0.41
SMA20-2.15% SMA50-22.60% SMA200-64.57% Trades Volume147,521 Change-3.35%
Date Action Analyst Rating Change Price Target Change
Oct-01-21Initiated Ascendiant Capital Markets Buy $8
Jul-12-24 08:00AM
May-22-24 08:00AM
May-14-24 08:00AM
May-09-24 09:30AM
08:00AM Loading…
May-07-24 08:00AM
Apr-02-24 05:41PM
Mar-26-24 05:52AM
Dec-18-23 12:03PM
Dec-11-23 09:30AM
Nov-20-23 08:00AM
Nov-16-23 08:00AM
Nov-13-23 08:00AM
08:00AM Loading…
Oct-30-23 08:00AM
Oct-23-23 09:31AM
Oct-02-23 09:30AM
Sep-22-23 08:00AM
Aug-30-23 09:30AM
Jun-22-23 09:30AM
Jun-13-23 08:00AM
May-24-23 08:00AM
May-11-23 12:38PM
Apr-04-23 06:30AM
Apr-03-23 09:35AM
09:34AM Loading…
Mar-22-23 09:30AM
Mar-17-23 07:09AM
Mar-16-23 08:00AM
Jan-26-23 08:00AM
Jan-04-23 08:00AM
Dec-28-22 08:00AM
Dec-13-22 03:52PM
Nov-22-22 08:05AM
Nov-15-22 08:00AM
Oct-31-22 08:00AM
Oct-11-22 10:03AM
Oct-05-22 12:45PM
Sep-29-22 12:29PM
Sep-22-22 08:00AM
Aug-25-22 07:13AM
Jul-24-22 08:41AM
Jul-18-22 10:42AM
Jun-20-22 09:22AM
Jun-03-22 08:00AM
May-17-22 08:00AM
May-06-22 09:02AM
May-05-22 08:00AM
May-04-22 06:25AM
Apr-28-22 06:30AM
Apr-11-22 08:00AM
Apr-06-22 10:15AM
Apr-04-22 08:00AM
Mar-28-22 08:00AM
Mar-18-22 06:31AM
Jan-13-22 04:00AM
Dec-17-21 09:54AM
Dec-14-21 06:35PM
Nov-30-21 08:30AM
Nov-11-21 07:17AM
Oct-01-21 09:24AM
Sep-30-21 01:45PM
Sep-16-21 06:09AM
Sep-15-21 06:29AM
Sep-13-21 06:30AM
Aug-17-21 10:59AM
Aug-04-21 06:30AM
Jul-30-21 06:30AM
Jul-28-21 03:07PM
Jul-26-21 04:03PM
Jul-23-21 12:44PM
Jul-12-21 06:00AM
Jul-01-21 06:45AM
Jun-28-21 03:59PM
Jun-17-21 04:30PM
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AULT MILTON C IIIDirectorApr 19 '24Buy0.691,000688771,699Apr 23 08:00 PM
AULT MILTON C IIIDirectorApr 01 '24Buy0.91334304770,699Apr 03 05:00 PM
AULT MILTON C IIIDirectorJan 05 '24Buy1.025,0005,092768,365Jan 09 04:30 PM
AULT MILTON C IIIDirectorJan 05 '24Buy1.062,0002,127770,365Apr 01 04:30 PM
AULT MILTON C III10% OwnerDec 26 '23Buy0.9050045026,032Dec 27 04:30 PM
AULT MILTON C III10% OwnerDec 22 '23Buy0.92200185166,866Dec 27 04:30 PM
Katzoff David JChief Financial OfficerSep 26 '23Buy0.1953,00010,23481,000Sep 26 06:01 PM